Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medical oxygen (100% O2) is a gas therapy being investigated for the prevention of contrast-induced nephropathy (CIN), particularly in patients with pre-existing chronic kidney disease undergoing coronary angiography. The intervention, known as normobaric hyperoxygenation, involves the administration of pure oxygen via a mask or nasal cannula to increase the partial pressure of oxygen in the arterial blood. The primary mechanism of action is to counteract renal medullary hypoxia, a critical factor in the pathogenesis of CIN. Contrast media can cause intense vasoconstriction and increased metabolic demand in the renal medulla; by enhancing systemic oxygen delivery, this therapy aims to maintain adequate tissue oxygenation in the kidney, thereby preventing acute kidney injury and preserving renal function following exposure to iodine-based contrast agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on medical oxygen.